title: Successful treatment of two patients with recurrent endometrial cancer by weekly paclitaxel.
abstract: OBJECTIVE
  The aim of this study was to evaluate the toxicity and efficacy of weekly paclitaxel in patients with recurrent endometrial cancer.
  
  
  METHODS
  Paclitaxel (70 mg/m(2) by 1-h infusion weekly) was administered to two patients with recurrent endometrial cancer of the lung.
  
  
  RESULTS
  After 5 cycles, both patients with platinum-resistant disease achieved clinical partial responses confirmed by computed tomography (CT) scan. The serum CA125 levels of case 1 decreased to cut-off level. The response duration of both patients was 4 months. The toxicity was acceptable and probably less pronounced than that characterize of the standard tri-weekly schedules.
  
  
  CONCLUSIONS
  Although conclusions regarding survival are premature, weekly paclitaxel might offer better quality of life during treatment.
authors.affiliation: Department of Obstetrics and Gynecology, Kurume University School of Medicine, 67 Asahi-machi, Kurume City, 830-0011, Fukuoka, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Ota
authors.forename: T
authors.initials: T
authors.lastname: Sugiyama
authors.forename: K
authors.initials: K
authors.lastname: Ushijima
authors.forename: K
authors.initials: K
authors.lastname: Komai
authors.forename: K
authors.initials: K
authors.lastname: Fujiyoshi
authors.forename: N
authors.initials: N
authors.lastname: Hirai
authors.forename: T
authors.initials: T
authors.lastname: Nishida
authors.forename: T
authors.initials: T
authors.lastname: Kamura
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D018394:CA-125 Antigen; D017239:Paclitaxel